Skip to main content

View full-text article in PMC

. 2021 Jul 2;20:132. doi: 10.1186/s12933-021-01322-6

Table 3.

2DE structural and functional parameters at 2 weeks

	Level	Parameter	Group
	Level	Parameter	Control	Empagliflozin
Apical level	Systolic	LVESA [mm²]	47.5 ± 4.3^***	54.4 ± 5.1^***
	Systolic	LVIDs [mm]	7.1 ± 0.4^***	7.9 ± 0.5^***
	Diastolic	LVEDA [mm²]	69.3 ± 4.4^***	74.3 ± 5.3^***
	Diastolic	LVIDd [mm]	8.8 ± 0.4^***	9.3 ± 0.4^***
	Function	FS [%]	19.1 ± 3.3^**	15.1 ± 4.0^**
		FAC [%]	33.6 ± 3.0^***	27.2 ± 3.5^***
		EF [%]	42.9 ± 5.4^**	34.9 ± 6.4^**
Papillary muscles level	Systolic	LVESA [mm²]	47.1 ± 3.4^***	52.4 ± 4.0^***
	Systolic	LVIDs [mm]	7.8 ± 0.4^***	7.5 ± 0.5^***
	Diastolic	LVEDA [mm²]	78.4 ± 3.8^***	80.2 ± 4.5^***
	Diastolic	LVIDd [mm]	9.5 ± 0.2^***	9.3 ± 0.3^{*** #}
	Function	FS [%]	17.8 ± 2.7^***	20.1 ± 3.2^**
		FAC [%]	39.3 ± 2.9^***	35.7 ± 3.4^**
		EF [%]	40.2 ± 4.6^***	45.4 ± 5.4^**

Abbs. as in Table 2. ** P < 0.01 vs. baseline and *** P < 0.001 vs. baseline, ^# P < 0.05 vs. damage group